logo logo


US calls for additional FTA measures to ensure transparency in medicine pricing in Korea
With just days left before the implementation of the US-Korea free trade agreement Washington is drawing attention to a little publicized area of the trade treaty, the part covering the pricing of medicine in Korea. The US says it wants more transparency; the Korean pharmaceutical industry says it wants to maintain control over pricing domestically.
TPP negotiators turn to pharmaceutical reimbursement
Negotiations of the Transpacific Partnership Agreement (TPP) have turned to discussions of the pharmaceutical reimbursement chapter. This issue is highly controversial and represents a very recent shift in US trade policy.
Does EU/India free trade agreement spell the end of cheap drugs for poor countries?
After four years of negotiations, campaigners fear India is about to sign a trade deal with the EU which will stop the flow of cheap life-saving drugs to the developing world
Act Up-Paris confront Karel De Gucht on ACTA and EU-India FTA
Supporting the ongoing Global Week of Action on the EU-India FTA, Pauline Londeix of Act Up-Paris today confronted the European Commission for Trade, Karel de Gucht at a “Civil Society dialogue on Trade, Growth and development” at the European Commission. De Gucht reportedly leaves for India tomorrow for the EU-India Summit on 10th February 2012 where the E.C. is putting pressure on the Indian government to announce political trade-offs in the EU-India FTA.
Network calls for rejection of free trade agreement
Fiji Network for Positive People believes that the Asia Pacific Network of People Living with HIV/AIDS meeting will be an opportune time to advocate for continuing availability of generic Anti Retro Viral treatment in the face of threats from Free Trade Agreement negotiations.
AMCHAM interferes in domestic policies through FTA
Under the Korea-US Free Trade Agreement (KORUS FTA), Korean civil servants would be excluded from the Health Insurance Review and Assessment Service (HIRA)’s process of price determination. Instead independent review procedures could be used to set prices for medicines and medical supplies. This has caused concern among health care groups who worry that multinational pharmaceutical companies could use the independent review procedure to change the Korean government’s medicine prices.
NGO asks European Commission not to push India to accept IP provisions in EU-India FTA
As the 14th round of negotiations on the EU-India free trade agreement is held in Delhi, an NGO working in the health sector has urged the European Union not to push India to accept IP provisions in the deal
EU-India FTA negotiations: DNP+ protest
DNP+ believes that IP should be completely be removed from the trade negotiations.
Legal scholars release critical analysis of US proposals for IP and pharmaceutical chapters of the TPP
The scholars’ analysis concludes that the "US proposals, if adopted, would upset the current international framework balancing the minimum standards for exclusive rights for media and technology owners, on the one hand, and the access rights of the public, competitors, innovators and creators, on the other."
TPP - US TBT proposal (2011)
Citizen Trade Campaign has released this proposed text from the US on technical barriers to trade relating to medical devices and pharmaceuticals under the Trans Pacific Partnership
Indian pharma industry to gain from free trade agreement with Gulf nations
The Indian pharmaceuticals and chemicals industry will be among the biggest beneficiaries of a free trade agreement between the GCC and India, a leading banker in the region has said.
US seeks to allay drug access concerns in TPP talks
The Obama administration on Monday sought to allay concerns that the U.S. push for stronger drug patent protections in a Transpacific trade deal would raise the cost of life-saving treatments out of the reach of the region’s poor people.
Malaysian declaration on the TPPA and access to medicines
Call for all civil society groups, people living with HIV, all communities facing communcable, chronic and/or non-communicable diseases in the TPPA signatory countries to join forces to halt any & all trade agreements that restrict access to generic medicines.
New trade agreement threatens Australia’s laws on medicines and tobacco
Australia leads the world in many areas of public health but the Federal Government could be negotiating our achievements away, according to Dr Patricia Ranald, Convenor, Australian Fair Trade and Investment Network
ICAAP10 2011: No safe avenue to address your concerns
The 10th International Conference on AIDS in Asia and the Pacific (ICAAP10) has been turned upside down completely
Protestors attacked by police at international AIDS conference
An anti-Free Trade Agreement protest that took place outside an International Congress on AIDS in the Asia Pacific (ICAAP) in Busan, South Korea, on 27 August was violently attacked by police.
House legislators lobby to exclude 12-year data exclusivity period from free trade agreement
Last week, a group of seven House Democrats, led by Rep. Henry Waxman (D-CA), sought to have the 12-year data exclusivity period provided by the biosimilar approval pathway of the US’ Patient Protection and Affordable Care Act excluded from the Trans-Pacific Partnership agreement
DoP to convey concerns of industry over proposed FTAs, TPPA to commerce ministry
India’s Department of Pharmaceuticals will take up issues with the Commerce Ministry regarding the proposed Trans Pacific Partnership Agreement which is likely to have adverse impact on the Indian pharma products, and other such Free Trade Agreements in the pipeline.
A trade barrier to defeating AIDS
The new strategy is to treat people in Egypt, Paraguay, Turkmenistan or China — middle-income countries, all — as if they or their governments could pay hundreds or even thousands of dollars a year each for AIDS drugs.
Impact Assessment of CETA IPR chapter
CETA IPR chapter will likely have a slight positive effect on specific industries in the EU, such as agri-food companies using geographical indications. It would also benefit the Canadian publishing industry and the innovative pharmaceutical industry. At the same time, an IPR chapter in CETA could lead to notable negative effects in Canada, for example via higher prices on educational and pharmaceutical products.